ACTH-secretingpheochromocytomaisaveryrarecauseofCushing'ssyndrome,withahighmorbidityandmortality risk due to both cortisol and catecholamines excess. We report the case of a 45-year-old female patient with a 3 cm, high-density,leftadrenalmass,diagnosedasanACTH-secretingpheochromocytoma.Thebiochemicalsensitivityofthe tumor to somatostatin analogues was tested by a 100 μgs.c.octreotideadministration,whichledtoanACTHandcortisol reduction of 50 and 25% respectively. In addition to alpha and beta blockers, preoperative approach to laparoscopic adrenalectomy included octreotide, a somatostatin analogue, together with ketoconazole, in order to achieve an adequate pre-surgicalcontrolofcortisolrelease.HistopathologicalassessmentconfirmedanACTH-secretingpheochromocytoma expressing type 2 and 5 somatostatin receptors (SSTR-2 and -5).
• Surgical removal of the adrenal mass is the gold standard treatment, but adequate medical therapy is required preoperatively to improve the surgical outcome and to avoid major complications.
• Somatostatin analogs, in addition to other medications, may represent a useful therapeutic option for the presurgical management of selected patients.
• In this sense, the octreotide challenge test is a useful tool to predict favorable therapeutic response to the treatment.
Background
Cushing's syndrome (CS) is an uncommon disorder, with an incidence of 0.7-2.4 cases per million per year (1) . The majority of cases result from adrenocorticotropin (ACTH) hypersecretion, usually from a pituitary adenoma. In a smaller percentage of cases, ACTH is over-secreted from a non-pituitary source, such as bronchial carcinoid, smallcell lung carcinoma or thyroid medullary carcinoma (1) . CS resulting from an ACTH-secreting pheochromocytoma is an even more rare and challenging condition that combines hypercortisolism and catecholamine excess, leading to severe and potentially life-threatening complications (2) . About 60 cases have been reported in literature so far (2) . The gold standard treatment of this condition is adrenalectomy, preceded by adequate medical preparation to obtain adequate control of hormonal hypersecretions. Here, we report a case of CS due to an 
Investigation
Results of the hormonal assessment are depicted in Table 1 . Urinary and serum cortisol and plasma ACTH were markedly increased and dexamethasone 1 mg overnight failed to suppress serum cortisol levels, consistently with a condition of ACTH-dependent Cushing's syndrome. Aldosterone/renin ratio was within the normal limits. Ancillary findings were secondary hypothyroidism, central hypogonadism, and low IGF-1 levels, as usually observed in cases of overt hypercortisolism. Serum CRH stimulation test failed to significantly increase both serum cortisol and plasma ACTH levels (Table 1) . Serum cortisol levels remained unchanged after high-dose (8 mg) dexamethasone overnight administration. Taken together, all these findings were consistent with a non-pituitary (ectopic) source of the ACTH secretion. Following a s.c. 100 μg octreotide administration, a 50% decrease in ACTH levels and 25% decrease in cortisol levels were observed ( Table 2) . The octreotide challenge test was performed under the surveillance of an expert physician, with a close monitoring of vital parameters.
A computed tomography (CT) of the thorax and abdomen identified a 3 cm left adrenal mass, showing features consistent with a non-adenoma ( Fig. 1 ). Magnetic resonance imaging (MRI) of the pituitary gland was normal. Further hormonal investigation showed high concentrations of urinary catecholamines Preoperative biochemical controls showed a significant reduction of plasma ACTH (204 pg/mL) and serum cortisol (46.6 μg/dL) levels. An optimal control of blood pressure and pulse rate was achieved. Subsequently, the patient underwent a laparoscopic left adrenalectomy without any complication. Histopathological and immunohistochemical assessment confirmed an ACTHproducing pheochromocytoma expressing somatostatin receptors (SSTR) 2 and 5 (Fig. 2) . The analysis of encoding ubiquitin-specific protease 8 (USP8) gene revealed no mutations. Postoperatively there was a rapid and complete remission of hypertension, hypokalemia and hyperglycemia. The patient discontinued all the hypoglycemic agents. Plasma ACTH showed a rapid and significant decrease to 5 pg/mL 3 days after surgery. To avoid adrenal insufficiency due to the chronic suppression of the corticotropic axis, transient replacement therapy with hydrocortisone was introduced. There was a rapid recovery of the corticotropic axis that allowed the withdrawal of hydrocortisone after 15 days.
Outcome and follow-up
One month after adrenalectomy, cortisol suppression after dexamethasone 1 mg overnight confirmed the complete resolution of endogenous hypercortisolism. In addition, urinary metanephrines normalized, (105.3 µg/24 h), and CGA decreased to normal values (1.2 nmol/L). At 4-year follow-up, there were not any biochemical, clinical or radiological sign of recurrence.
Discussion
ACTH-secreting pheochromocytoma represents a very rare and distinctive cause of CS, where clinical manifestations due to cortisol and catecholamines excess coexist. About 60 cases have been reported in literature so far (2) . The syndrome predominantly occurs in women, with typical features including severe hypercortisolism, hypokalemia, rapidly worsening diabetes mellitus and hypertension, large adrenal tumor, and lack of typical phenotype of Cushing syndrome probably due to the fast development of hypercortisolism (2) . Early diagnosis is often difficult, but is mandatory in order to avoid serious and potentially fatal complications and to guarantee an adequate pre-and post-surgical management. However, consensus regarding the optimal strategy regarding the perioperative clinical workup of such patients is still lacking, due to the rarity of the syndrome and the anecdotal reports presented in literature.
Here we report the efficacy of octreotide administration combined with ketoconazole, doxazosin and atenolol in the management of a 45-year woman with an ACTHsecreting pheochromocytoma, allowing an adequate presurgical control of cortisol and catecholamines excess.
Expression of SSTRs has been documented in pheochromocytomas (3), but clinical reports on the efficacy of somatostatin analogs published so far have yielded conflicting results (4, 5) , due, at least in part, to the wide heterogeneity of SSTRs expression in the tumor and to their different affinity to the drugs (6) . Identification of specific parameters predicting a favorable response to therapy is therefore crucial to select patients who may benefit from somatostatin analogs.
Ruggeri et al. (6) reported the case of a patient harboring a CRH-secreting pheochromocytoma, successfully treated with octreotide based on a positive octreotide scintigraphy. In that case, immunohistochemistry revealed the expression of SSTR1, SSTR2A, and SSTR2B receptor subtypes on tumor cells. However, Uwaifo et al. (7) described three cases of ectopic ACTH-dependent CS where pentetreotide scan failed to predict the therapeutic response to somatostatin analogs, with one patient even developing a paradoxical increase in ACTH and cortisol levels after a single octreotide administration. Similar observations have also been reported by other authors (8) . Uwaifo et al. (7) suggested performing an octreotide challenge test to predict the ACTH and cortisol response to therapy but, to our knowledge, no reports are available in the literature on this topic in patients with ACTHsecreting pheochromocytoma.
To date, there is no established protocol to acutely test the hormonal sensitivity to somatostatin analogs in CS. We decided to perform a single acute challenge with 100 μg octreotide, similarly to what has been described in acromegaly (9) . The significant reduction of circulating ACTH levels prompted us to associate octreotide to ketoconazole in the pre-surgical workup of the patient, that in a few days led to a further reduction of ACTH together with cortisol levels. The combination of the two drugs with doxazosin and atenolol allowed an optimal pre-and intra-operative control of blood pressure, pulse rate, glycemic profile and electrolyte homeostasis.
In this setting, the effects of octreotide cannot be isolated from those of the associated drugs. Some authors, however, reported that ketoconazole alone may be unable to adequately control hypercortisolism in ACTH-secreting pheochromocytoma (10) , exposing the patients to the wellknown perioperative complication due to cortisol excess.
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